Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic ar...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ann Rheum Dis
Main Authors: Smolen, Josef S, Mease, Philip, Tahir, Hasan, Schulze-Koops, Hendrik, de la Torre, Inmaculada, Li, Lingnan, Hojnik, Maja, Sapin, Christophe, Okada, Masato, Caporali, Roberto, Gratacós, Jordi, Goupille, Philippe, Liu Leage, Soyi, Pillai, Sreekumar, Nash, Peter
格式: Artigo
語言:Inglês
出版: BMJ Publishing Group 2020
主題:
Psoriatic Arthritis
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509529/
https://ncbi.nlm.nih.gov/pubmed/32660977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217372
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍